Copyright 2009  by "International Journal of Pharmaceutica Research and Development"    All Rights reserved    E-Mail: info@ijprd.com
Welcome to "International Journal of Pharmaceutical Research and Development"  i.e. "IJPRD"
HOW TO PREPARE   
YOUR PAPER
What's New | Feedback | Copyright and Disclaimer
TODAY IS
Abstract Content
Model Abstract
Summary Content
Model Summary

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Copyright 2009  by "International Journal of Pharmaceutica Research and Development"    All Rights reserved    E-Mail: info@ijprd.com
Welcome to "International Journal of Pharmaceutical Research and Development"  i.e. "IJPRD"
HOW TO PREPARE   
YOUR PAPER
What's New | Feedback | Copyright and Disclaimer
Online Since : March 2009
TODAY IS
Abstract Content
Model Abstract
Summary Content
Model Summary

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT
DRY POWDER INHALERS FOR PULMONARY DRUG DELIVERY SYSTEM

Swati Modgil1*,
Vandna Dhiman
1, Jaspreet Ramana1,  Upendra K Jain1

1
Chandigarh Group of Colleges, Landran, Mohali Punjab, India.
May - 2013 / Volume - 5/Issue - 3
( Total Articles =20)
May 2013 Issue
ABSTRACT
Pulmonary drug delivery remains the preferred route for administration of various drugs. Dry Powder Inhalers are found to be good alternatives to metered-dose inhalers (MDIs) has accelerated recently in a bid to find effective products that do not use chlorofluorocarbon propellants. A wide range of Dry powder inhalers (DPIs) devices are currently available on the market to deliver drugs into lungs with a view to maximize drug delivery with low variability and high efficacy.
For the good DPI formulation particle size of API must be present in size range about 1-10 m for maximizing its effect and also guarantee that the patient gets the same dose every time at different airflow rate. DPI are formulated using four types of formulation strategies such as; Carrier Free, Drug Carrier, Drug Additive, Drug Carrier Additive. In the last decade many patents have been filed claiming improvement in aerosol performance of dry powder inhalers through the use of (i) incorporation of fines of carrier particles to occupy active sites on the surface and use of hydrophobic carriers to facilitate deaggregation through reduced surface energy and particle interaction (ii) reducing aerodynamic diameters through particle engineering and incorporating drug into porous or low particle density, and/or (iii) preparing less cohesive and adhesive particles through corrugated surfaces, low bulk density, reduced surface energy and particle interaction and hydrophobic additives.

KEYWORDS :
inhalation therapy, pulmonary drug delivery, carrier lactose, physico-chemical characterization; particle size.
[ Full Text - PDF ]
Share This Article on Social Networking's or You can invite friends to this Article.  !!